TW201241182A - Method of production of sialylated antibodies - Google Patents

Method of production of sialylated antibodies Download PDF

Info

Publication number
TW201241182A
TW201241182A TW101106076A TW101106076A TW201241182A TW 201241182 A TW201241182 A TW 201241182A TW 101106076 A TW101106076 A TW 101106076A TW 101106076 A TW101106076 A TW 101106076A TW 201241182 A TW201241182 A TW 201241182A
Authority
TW
Taiwan
Prior art keywords
ser
val
thr
pro
lys
Prior art date
Application number
TW101106076A
Other languages
English (en)
Chinese (zh)
Inventor
Francis Blanche
Beatrice Cameron
Bruno Genet
Fabienne Soubrier
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of TW201241182A publication Critical patent/TW201241182A/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/40Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41Glycosylation, sialylation, or fucosylation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TW101106076A 2011-02-24 2012-02-23 Method of production of sialylated antibodies TW201241182A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11305200 2011-02-24
EP11306090 2011-09-01

Publications (1)

Publication Number Publication Date
TW201241182A true TW201241182A (en) 2012-10-16

Family

ID=45774189

Family Applications (1)

Application Number Title Priority Date Filing Date
TW101106076A TW201241182A (en) 2011-02-24 2012-02-23 Method of production of sialylated antibodies

Country Status (6)

Country Link
US (1) US20140046032A1 (enExample)
EP (1) EP2678357A1 (enExample)
JP (1) JP2014508759A (enExample)
AR (1) AR085302A1 (enExample)
TW (1) TW201241182A (enExample)
WO (1) WO2012113863A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
IL275376B2 (en) * 2013-03-11 2024-01-01 Genzyme Corp Hyperglycosylated binding polypeptides
EP2830651A4 (en) 2013-03-12 2015-09-02 Abbvie Inc HUMAN ANTIBODIES THAT BIND TNF-ALPHA AND PREPARATION METHODS
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US10450361B2 (en) 2013-03-15 2019-10-22 Momenta Pharmaceuticals, Inc. Methods related to CTLA4-Fc fusion proteins
ES2802274T3 (es) 2013-05-02 2021-01-18 Momenta Pharmaceuticals Inc Glicoproteínas sialiladas
ES2708759T3 (es) 2013-05-13 2019-04-11 Momenta Pharmaceuticals Inc Procedimientos para el tratamiento de la neurodegeneración
CA2908407C (en) 2013-05-29 2022-06-14 F. Hoffmann-La Roche Ag Quantitative control of sialylation
HK1221741A1 (zh) 2013-07-05 2017-06-09 F. Hoffmann-La Roche Ag 用於使用N-末端截短的β-半乳糖苷-α-2,6-唾液酸转移酶变体的糖蛋白的单-和二唾液酸化的方法
EP2824176A1 (en) 2013-07-11 2015-01-14 Siamed'xpress Methods for producing sialylated therapeutic proteins
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
EP3058084A4 (en) * 2013-10-16 2017-07-05 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
EP4640239A2 (en) 2014-03-19 2025-10-29 Genzyme Corporation Site-specific glycoengineering of targeting moieties
SG11201700446XA (en) 2014-07-21 2017-02-27 Glykos Finland Oy Production of glycoproteins with mammalian-like n-glycans in filamentous fungi
EP3037527A1 (en) * 2014-12-22 2016-06-29 F. Hoffmann-La Roche AG Sialyltransferase without CMP-dependent sialidase activity
EP3237608B1 (en) * 2014-12-22 2019-10-09 F. Hoffmann-La Roche AG Cmp-dependent sialidase activity
US11337975B2 (en) 2016-11-23 2022-05-24 Acetylon Pharmaceuticals, Inc. Pharmaceutical combinations comprising a histone deacetylase inhibitor and a CD38 inhibitor and methods of use thereof
EP3354278A1 (en) * 2017-01-31 2018-08-01 Sanofi Neuronal cell protective effect of antibodies specific for the protofibrillar form of the beta-amyloid peptide
FR3080376B1 (fr) * 2018-04-20 2022-12-09 Lab Francais Du Fractionnement Autoanticorps hautement sialyles et leurs utilisations
MA55529A (fr) 2019-04-03 2022-02-09 Genzyme Corp Polypeptides de liaison anti-alpha bêta tcr à fragmentation réduite
TWI869528B (zh) 2020-01-13 2025-01-11 美商威特拉公司 C5ar1抗體分子及其用途
WO2023086793A1 (en) * 2021-11-09 2023-05-19 Amgen Inc. Production of therapeutic proteins
WO2025101901A1 (en) * 2023-11-10 2025-05-15 The Board Of Trustees Of The Leland Stanford Junior University Use of sialylated ivig or igg fc region-containing protein for preventing or treating respiratory virus diseases

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5792632A (en) 1992-05-05 1998-08-11 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
US5474896A (en) 1992-05-05 1995-12-12 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5830729A (en) 1996-04-18 1998-11-03 Institut Pasteur I Sce I-induced gene replacement and gene conversion in embryonic stem cells
US20020045207A1 (en) * 1997-10-31 2002-04-18 Lynne A. Krummen Glycoprotein production process
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1309341A2 (en) 2000-07-07 2003-05-14 Lars Lannfelt Prevention and treatment of alzheimer's disease
DE60236182D1 (de) 2001-09-14 2010-06-10 Cellectis Zufällige integration von polynukleotide nach in vivo linearisierung
JP2006518372A (ja) 2003-01-28 2006-08-10 セレクティス 脊椎動物の体組織においてエクスビボかつイントトで相同的組換えを誘発するためのメガヌクレアーゼの使用およびその応用
DK1896071T3 (en) * 2005-06-30 2015-05-26 Janssen Biotech Inc Methods and compositions with increased therapeutic activity
ES2376083T3 (es) 2005-10-21 2012-03-08 Genzyme Corporation Terapéuticos basados en anticuerpos con actividad adcc mejorada.
WO2008057634A2 (en) 2006-10-26 2008-05-15 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US20080206246A1 (en) 2006-04-05 2008-08-28 Ravetch Jeffrey V Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
MX358175B (es) 2005-12-12 2018-08-08 Ac Immune Sa Anticuerpos monoclonales especificos 1-42 beta con propiedades terapeuticas.
CN101432301B (zh) 2006-04-05 2014-01-08 洛克菲勒大学 具有增强的抗炎性和降低的细胞毒性特性的多肽以及相关方法
JP2010512306A (ja) * 2006-10-27 2010-04-22 ザ ロックフェラー ユニバーシティー 抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法
PE20081250A1 (es) * 2006-11-28 2008-10-07 Centelion FUSIONES Fc CON RECEPTOR PARA FGF SOLUBLE MODIFICADAS, CON ACTIVIDAD BIOLOGICA MEJORADA
MY159201A (en) 2007-08-29 2016-12-30 Sanofi Aventis Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
AU2008311366B2 (en) 2007-10-05 2015-03-12 Ac Immune S.A. Use of anti-amyloid beta antibody in ocular diseases
AU2008312611A1 (en) 2007-10-15 2009-04-23 Centocor, Inc. Human anti-amyloid antibodies, compositions, methods and uses
WO2009054985A1 (en) 2007-10-25 2009-04-30 Sangamo Biosciences, Inc. Methods and compositions for targeted integration
EP2226081A4 (en) 2007-10-25 2011-10-12 Univ Kagoshima PEPTIDE VACCINE WITH A MIMIC MOLECULE OF AMYLOID PEPTIDE
CN104098695B (zh) 2007-10-29 2018-09-07 道健康生活医药株式会社 抗体及其应用
SI2207568T1 (sl) 2007-11-16 2017-11-30 The Rockefeller University Protitelesa specifična za protifibrilno obliko beta-amiloidnega proteina
UY31520A1 (es) 2007-12-11 2009-08-03 Proteinas de union a antigenos
EP2233502A1 (en) 2009-03-27 2010-09-29 Deutsches Rheuma-Forschungszentrum Berlin Sialylated antigen-specific antibodies for treatment or prophylaxis of unwanted inflammatory immune reactions and methods of producing them
FR2945538B1 (fr) * 2009-05-12 2014-12-26 Sanofi Aventis Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide.
US10087236B2 (en) * 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering

Also Published As

Publication number Publication date
WO2012113863A1 (en) 2012-08-30
JP2014508759A (ja) 2014-04-10
AR085302A1 (es) 2013-09-18
EP2678357A1 (en) 2014-01-01
US20140046032A1 (en) 2014-02-13

Similar Documents

Publication Publication Date Title
TW201241182A (en) Method of production of sialylated antibodies
AU2018266711B2 (en) Anti-CD3-binding domains and antibodies comprising them, and methods for their generation and use
JP7765397B2 (ja) 新規抗lilrb4抗体および派生産物
CA2946503C (en) Modified antigen binding polypeptide constructs and uses thereof
JP5511686B2 (ja) 抗cd4抗体
KR20100074220A (ko) Cdr의 아미노산 치환에 의해 항체의 등전점을 개변하는 방법
CA2963760A1 (en) Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
KR102669686B1 (ko) 변형된 항원 결합 폴리펩티드 작제물 및 이의 용도
TW200808830A (en) Mutant polypeptide having effector function
TWI781973B (zh) 用於以活體外進行抗體糖基化工程之方法
KR20140108520A (ko) CD1d에 대한 항체
CN119685431A (zh) 用于体外糖工程化抗体的方法
MX2013015061A (es) Anticuerpo anti-cxcr4 con funciones efectoras y su uso para el tratamiento del cancer.
JP2024112905A (ja) 抗体依存性細胞介在性細胞傷害の調節方法
TW201441258A (zh) 用於hiv預防及治療的醣修飾抗cd4抗體
US20250277041A1 (en) Anti-fgfr2 adcc enhanced antibody and use thereof
US20250101104A1 (en) Bispecific molecule with tunable affinity to a targeted antigen
CN118414356A (zh) 具有增强的效应子功能的生物合成单价结合分子
JP7245793B2 (ja) 安定化したキメラFab
US20250206824A1 (en) GLYCOENGINEERED Fc VARIANT POLYPEPTIDES WITH ENHANCED EFFECTOR FUNCTION
US20250263481A1 (en) Monoclonal Antibodies Against CLDN18.2 and FC-Engineered Versions Thereof
RU2832921C1 (ru) Модифицированные антигенсвязывающие полипептидные конструкции и их применение
TW202405000A (zh) Sars-cov2抗體及其用途
CN118475614A (zh) 具有增强的效应子功能的生物合成双互补位或双特异性结合分子
HK40011892B (zh) 用於体外糖工程化抗体的酶的再使用